<DOC>
	<DOCNO>NCT01908712</DOCNO>
	<brief_summary>The overall objective trial provide aftercare treatment Lamazym evaluate safety repeat Lamazym i.v . treatment subject alpha-Mannosidosis previously participate Lamazym-trial .</brief_summary>
	<brief_title>Lamazym Aftercare Study FR Designed Provide Treatment French Patients</brief_title>
	<detailed_description>This trial provide aftercare treatment Lamazym French patient .</detailed_description>
	<mesh_term>Mannosidase Deficiency Diseases</mesh_term>
	<mesh_term>alpha-Mannosidosis</mesh_term>
	<criteria>subject must participate previous Lamazymtrials : phase 2b : 201100435540 phase 3 : 201200097917 Subject subject legally authorize guardian ( ) must provide sign , inform consent prior perform trialrelated activity The subject his/her guardian ( ) must ability comply protocol Presence know clinically significant cardiovascular , hepatic , pulmonary , renal disease medical condition , opinion Investigator , would preclude participation trial Any medical condition serious intercurrent illness , extenuate circumstance , opinion Investigator , would preclude participation trial Pregnancy . Pregnant woman exclude . Before start fot treatment investigator woman childbearing potential perform pregnancy test decide whether need contraception Psychosis ; psychotic disease , also remission , exclusion criterion Planned major surgery , opinion Investigator , would preclude participation trial Adult patient , opinion Investigator , would unable give consent , legal protection guardianship total IgE &gt; 800 IU/mL Known allergy IMP excipients ( SodiumPhosphate , Glycine , Mannitol )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>